1. Home
  2. ZUMZ vs DMAC Comparison

ZUMZ vs DMAC Comparison

Compare ZUMZ & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zumiez Inc.

ZUMZ

Zumiez Inc.

N/A

Current Price

$28.61

Market Cap

363.1M

ML Signal

N/A

Logo DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc.

N/A

Current Price

$8.16

Market Cap

457.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ZUMZ
DMAC
Founded
1978
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
363.1M
457.2M
IPO Year
2005
N/A

Fundamental Metrics

Financial Performance
Metric
ZUMZ
DMAC
Price
$28.61
$8.16
Analyst Decision
Hold
Strong Buy
Analyst Count
1
4
Target Price
$18.00
$15.50
AVG Volume (30 Days)
313.5K
551.3K
Earning Date
12-04-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.49
N/A
Revenue
$916,909,000.00
N/A
Revenue This Year
$5.50
N/A
Revenue Next Year
$1.36
N/A
P/E Ratio
$59.11
N/A
Revenue Growth
2.81
N/A
52 Week Low
$11.31
$3.19
52 Week High
$31.70
$10.42

Technical Indicators

Market Signals
Indicator
ZUMZ
DMAC
Relative Strength Index (RSI) 62.24 49.85
Support Level $28.55 $8.40
Resistance Level $29.68 $10.14
Average True Range (ATR) 1.19 0.72
MACD -0.05 -0.08
Stochastic Oscillator 48.86 15.04

Price Performance

Historical Comparison
ZUMZ
DMAC

About ZUMZ Zumiez Inc.

Zumiez Inc is a United-States-based specialty retailer engaged in the sale of apparel, footwear, accessories, and hard goods. The company provides merchandise with cultural elements coming from fashion, music, art from action sports, streetwear, and other lifestyles. The company operates under the brands Zumiez, Fast Times, and Blue Tomato, and through both physical stores and websites. The majority of the company's stores are located in the U.S., with the rest in Canada, Australia, and Europe. The U.S. market contributes to the majority of the company's revenue.

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Share on Social Networks: